Natera Inc

Dilution score: 18/100 (LOW), 24.0 months cash

Short interest: 2.72% of float, squeeze risk: LOW

SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trial.

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.

Understanding the Promise and Challenges of Tumor-Agnostic Therapy: Could One Size Really Fit All?

Circulating Tumor DNA Response In Urothelial Cancer

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for C

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.

Short interest: 2.9% of float, squeeze risk: MODERATE

Dilution score: 13/100 (LOW), 999.0 months cash

FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma.

HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results.

Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial.

Targeting cyclin-dependent kinases in cancer: emerging therapeutics and clinical strategies.

Tricuspid Valve Academic Research Consortium-2 (TVARC-2): Trial Design and Endpoints.

SW convergence: 36/100 (Bearish Convergence), 1 bullish / 1 bearish signals

Roadmap for developing MRD as an early endpoint for drug approval in lymphoma.

Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.

Short interest: 2.73% of float, squeeze risk: LOW

Dilution score: 16/100 (LOW), 24.0 months cash

Short interest: 2.74% of float, squeeze risk: LOW

SW convergence: 36/100 (Bearish Convergence), 2 bullish / 2 bearish signals

Tricuspid Valve Academic Research Consortium-2 (TVARC-2) Tricuspid Valve: Trial Design and Endpoints.

SW convergence: 50/100 (Neutral), 2 bullish / 1 bearish signals

<article class="bts-verified-summary" data-ticker="NTRA">
<p>Natera Inc (NTRA) is the lead sponsor of 9 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-1">[1]</a></sup>.</p>
<p>NTRA has 7 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-2">[2]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Natera+Inc%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">SEC EDGAR · 0001604821 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22NTRA%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

SEC EDGAR — 0001604821

Natera Inc (NTRA) — BioTechSigns Verified Summary

Natera Inc (NTRA) is the lead sponsor of 9 active clinical trials listed on ClinicalTrials.gov[1].

NTRA has 7 Form 4 insider filings recorded at the SEC in the past 30 days[2].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Natera+Inc%22&aggFilters=status%3Arec%2Cact
[2] SEC EDGAR, 0001604821. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22NTRA%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11

The ProActive registry is a longitudinal, multi-center study with a prospective arm observing clinical care for patients receiving physician ordered Prospera, an allograft rejection test, and a historical control arm collecting data on cases at the same sites whose kidney allograft rejection status was managed with Serum Creatinine SCr/estimated Glomerular Filtration Rate eGFR. This registry will compare patient management and outcomes in patients who receive Prospera (Prospera arm) to the outcomes of the historical control group (control arm) to determine Prospera's clinical utility. High-risk subjects defined as having a biopsy-demonstrated rejection event or at least one pre-existing Donor Specific Antibody DSA with total Mean Fluorescent Intensity MFI\>3000 or a calculated Panel Reactive Antibodies cPRA\>70% will be followed for an additional period up to 24 months in both the Prospera arm and historical control arm.

The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)

The LAMBDA 002 registry study is an observational, longitudinal, multi-center study observing patients undergoing lung transplant.

LAMBDA 002 (Lung Registry) Study

The ProTECT registry is an observational longitudinal, multi-center study observing patients undergoing heart transplant for whom Prospera testing is part of routine clinical care, who are enrolled within 60 days of heart transplantation.

Prospera Test Evaluation in Cardiac Transplant (ProTECT)

This is an open label Comparative Effectiveness Research (CER) study in which patients will be randomized at the site level to Prospera surveillance or EMB surveillance in a 2:1 ratio (Prospera to EMB) at each site.

Subjects will be enrolled into the study while under evaluation for heart transplantation or on the transplant waiting list prior to heart transplantation. All subjects will follow the center's standard of care surveillance schedule from transplant through 4 weeks post-transplantation. EMB during this phase is expected to occur roughly weekly or bi-weekly.

Study group assignment will take place at randomization. Subjects will be randomized 30 days (± 10 days) post-transplant to Prospera surveillance versus EMB surveillance in a 2:1 ratio. Rejection surveillance (Prospera Group and EMB Group) will be performed at times corresponding to the institutional standard of care schedule for rejection surveillance.

A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

The PROCEED-CRC study will prospectively collect blood samples from participants who are at average risk of colorectal cancer (CRC). Samples will be used for research use and the development of a blood-based CRC screening test.

The purpose of this research is to develop and validate a single gene Non-Invasive Prenatal Test. The development of this investigational single-gene noninvasive prenatal testing (sgNIPT) for conditions such as cystic fibrosis (CF), spinal muscular atrophy (SMA), Sickle cell disease, alpha thalassemia (a-thalassemia) and beta thalassemia (b-thalassemia) could provide information about the possibility that a child will be born with a serious health condition, in some cases in the absence of reproductive partner screening.

In order to develop a test for this purpose, investigators will collect blood samples and medical information from pregnant women who have pregnancies at higher risk for single gene disorders, such as those who are carriers for these conditions or affected by these conditions themselves, medical data from their reproductive partners in some cases, and either genetic testing results or a cheek swab sample from the newborn(s).

EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)

The FIND-CRC study is a prospective collection of samples and data from participants who are at average risk of developing colorectal cancer (CRC). Collected samples and data will be analyzed to evaluate the clinical performance of the Natera CRC Screening Test.

Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)

The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk HR+/HER2- early-stage breast cancer. Based on ctDNA test results, participants will either start CDK4/6 inhibitor therapy in addition to hormone therapy or continue hormone therapy with ongoing ctDNA surveillance. This study will compare outcomes to historical controls from the NataLEE trial to determine whether ctDNA-guided timing maintains efficacy while reducing unnecessary treatment. Participants will be followed for up to 9 years with regular blood draws, hormone therapy, imaging as needed, and quality-of-life assessments.

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's molecular residual disease (MRD) testing across multiple cancer types. The study aims to assess the ability of Natera's assays to detect circulating tumor DNA (ctDNA) as a marker for disease recurrence and treatment response.